Lumea
David (DJ) Dalton is a highly experienced professional who has excelled in various roles related to business development, sales, and strategic partnerships across multiple industries. His expertise lies in computational pathology, laboratory medicine advancements, and biomarker development tools. With a strong background in operations management and sales training, David has successfully contributed to the growth and success of companies like Eonic Aesthetics, LabCorp, and Paige. Currently serving as the Vice President of Strategic Sales at Lumea, David continues to drive innovative initiatives in digital pathology and AI collaborations. His educational background includes a PhD candidate in Business Analytics, an MBA with a healthcare concentration, and a degree in marketing and sales management.
Lumea
Lumea is reshaping the pathology landscape with innovative technology solutions that elevate and enhance the entire pathology ecosystem. Since its founding in 2013, Lumea has pioneered one of the first software platforms of its kind, offering a comprehensive suite of products, including proprietary specimen-handling consumables, a digitally-enabled Laboratory Information System (LIS), and a premier IMS/Viewer. Lumea’s unique approach to digital pathology not only increases cancer detection rates but also delivers a substantial return on investment in a cost-sensitive environment and ultimately sets a higher standard of patient care in cancer diagnostics. With over 1.5 million digital diagnoses, Lumea ranks among the top 5 digital pathology platforms for clinical use in the United States. For further insights into the transformative benefits of Lumea technology, visit lumeadigital.com.